the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension

Pulmonary Hypertension Clinical Trial

— CPETPH  

Official title:

the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02061787
• Other study ID #: CPETPH
• Status: Recruiting
• Start date: September 2010
• Est. completion date: September 8, 2030

Study information

• Verified date: July 2022
• Source: Chinese Pulmonary Vascular Disease Research Group
• Contact: Zhihong Liu, Doctor
• Phone: 8601088396590
• Email: zhihongliufuwai[@]163.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

cardiopulmonary exercise test evaluate patients with pulmonary hypertension before and after medical or balloon pulmonary angioplasty treatment

Description:

patients diagnosed with pulmonary hypertension, including pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, will be evaluated by cardio pulmonary exercise test before and after medical or balloon pulmonary angioplasty treatment

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 4000
• Est. completion date: September 8, 2030
• Est. primary completion date: September 8, 2030
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 5 Years to 100 Years

Eligibility

Inclusion Criteria:

• pulmonary arterial hypertension;( WHO1)

• chronic thromboembolic pulmonary hypertension;

• pulmonary arterial hypertension due to other cause;

Exclusion Criteria:

• massive hemoptysis;

• unable to accomplish cardiopulmonary exercise testing due to neuromuscular disorders;

• recent recurrent syncope;

• pulmonary hypertension due to hypoxia;

• pulmonary hypertension due to left heart diseases.

Related Conditions & MeSH terms

• Chronic Thromboembolic Pulmonary Hypertension
• Hypertension
• Hypertension, Pulmonary
• Pulmonary Arterial Hypertension
• Pulmonary Hypertension
• Schistosomiasis

Intervention

Device:
• balloon pulmonary angioplasty
patients with chronic thromboembolic pulmonary hypertension who underwent balloon pulmonary angioplasty

Locations

Country	Name	City	State
China	center of pulmonary vascular disease, Fuwai hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese Pulmonary Vascular Disease Research Group

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	all cause mortality	all cause mortality	5 years
Primary	mean pulmonary arterial pressure after treatment	the mean pulmonary arterial pressure of patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty treatment	5 years
Primary	achievement of low risk	patients with chronic thromboembolic pulmonary hypertension achievement of low risk after balloon pulmonary angioplasty	5 years
Secondary	deterioration of WHO function	deterioration of WHO function	5 years